Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for ZYME.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 270.70M
March 31, 2026 364.73M
December 31, 2025 228.80M
September 30, 2025 251.93M
June 30, 2025 281.38M
March 31, 2025 265.29M
December 31, 2024 225.78M
September 30, 2024 297.20M
June 30, 2024 330.15M
March 31, 2024 345.05M
December 31, 2023 374.33M
September 30, 2023 295.41M
June 30, 2023 340.09M
March 31, 2023 340.79M
December 31, 2022 492.23M
September 30, 2022 166.24M
June 30, 2022 241.83M
March 31, 2022 300.53M
December 31, 2021 252.61M
Date Value
September 30, 2021 307.76M
June 30, 2021 359.81M
March 31, 2021 411.47M
December 31, 2020 426.35M
September 30, 2020 471.86M
June 30, 2020 436.79M
March 31, 2020 487.66M
December 31, 2019 298.90M
September 30, 2019 335.10M
June 30, 2019 355.65M
March 31, 2019 180.31M
December 31, 2018 200.16M
September 30, 2018 150.00M
June 30, 2018 166.23M
March 31, 2018 70.03M
December 31, 2017 87.80M
September 30, 2017 49.09M
June 30, 2017 62.48M
March 31, 2017 26.79M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Theravance Biopharma, Inc. 387.66M
BridgeBio Pharma, Inc. 720.71M
Aprea Therapeutics, Inc. 41.23M
ACADIA Pharmaceuticals, Inc. 956.47M
Alnylam Pharmaceuticals, Inc. 3.308B